Go Pro
NASDAQ:GUTS

Fractyl Health Q2 2026 Earnings Report

Fractyl Health logo
$0.70 +0.02 (+3.22%)
As of 01:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Fractyl Health EPS Results

Actual EPS
N/A
Consensus EPS
-$0.15
Beat/Miss
N/A
One Year Ago EPS
N/A

Fractyl Health Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fractyl Health Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Monday, August 10, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Fractyl Health Earnings Headlines

[URGENT] Mode Mobile terms changing Aug 14
Mode Mobile has secured its Nasdaq ticker, $MODE, while still in the pre-IPO stage. More than 60,000 investors have already put over $100 million into the company, including original Shark Tank investor Kevin Harrington. The company reports 490M+ users, $115M+ in lifetime revenue, and $1B+ earned and saved by users across 170+ countries. Deloitte ranked Mode North America's #1 fastest-growing software company in 2023 after 32,481% growth. Pre-IPO shares are currently priced at 0.52 dollars, but that price is set to change on August 14.tc pixel
See More Fractyl Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fractyl Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fractyl Health and other key companies, straight to your email.

About Fractyl Health

Fractyl Health (NASDAQ:GUTS) is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine. This outpatient procedure is designed to interrupt disease-driving signals between the gut and the liver, pancreas and brain, with the aim of improving glycemic control and reducing liver fat. Fractyl has conducted multiple clinical trials across North America, Europe and Asia, and holds CE mark approval in the European Union for Revita DMR.

Fractyl Health is also developing next-generation therapies and combination approaches to expand the reach of its duodenal resurfacing technology. The company has initiated pivotal studies to support U.S. regulatory filings and is preparing for broader commercial roll-out following anticipated approvals. Fractyl’s management team includes industry veterans in interventional gastroenterology, clinical development and medical device commercialization, positioning the company to address the growing global burden of metabolic disease.

View Fractyl Health Profile